|
|
Volumn 6, Issue 4, 2014, Pages 799-802
|
|
Antibodies to watch in 2014: Mid-year update
a
a
NONE
|
|
Author keywords
Cancer; Clinical studies; European Medicines Agency; Food and Drug Administration; Immune mediated disorders; Monoclonal antibodies
|
|
Indexed keywords
BAVITUXIMAB;
BLINATUMOMAB;
CD19 ANTIGEN;
CD3 ANTIGEN;
CLIVATUZUMAB TETRAXETAN Y 90;
DARATUMUMAB;
DEXAMETHASONE;
DINUTUXIMAB;
DOCETAXEL;
DUPILUMAB;
ETROLIZUMAB;
GEMCITABINE;
INTERLEUKIN 4 RECEPTOR ALPHA;
INTERLEUKIN 6 RECEPTOR;
LENALIDOMIDE;
MONOCLONAL ANTIBODY;
MPDL 3280A;
MUCIN 1;
NIVOLUMAB;
PEMBROLIZUMAB;
PHOSPHATIDYLSERINE;
PROGRAMMED DEATH 1 LIGAND 1;
RAMUCIRUMAB;
SA 237;
SECUKINUMAB;
SILTUXIMAB;
UNCLASSIFIED DRUG;
VEDOLIZUMAB;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ASTHMA;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
HUMAN;
LUNG NON SMALL CELL CANCER;
MONOTHERAPY;
MULTIPLE MYELOMA;
MYELOOPTIC NEUROPATHY;
PANCREAS CANCER;
PHASE 3 CLINICAL TRIAL (TOPIC);
PHASE TRANSITION;
REVIEW;
UNITED STATES;
ANIMAL;
DRUG APPROVAL;
PUBLICATION;
ANIMALS;
ANTIBODIES, MONOCLONAL;
DRUG APPROVAL;
HUMANS;
PERIODICALS AS TOPIC;
UNITED STATES;
|
|
EID: 84903581591
PISSN: 19420862
EISSN: 19420870
Source Type: Journal
DOI: 10.4161/mabs.29282 Document Type: Review |
|
Times cited : (47)
|
|
References (3)
|
